WHO ICTRP trial
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE…
NL-OMON50248 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON50248 |
|---|---|
| Public title | A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR FIRST-LINE TREATMENT OF RET FUSION-POSITIVE, METASTATIC NON-SMALL CELL LUNG CANCER |
| Scientific title | A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR FIRST-LINE TREATMENT OF RET FUSION-POSITIVE, METASTATIC NON-SMALL CELL LUNG CANCER - BO42864 AcceleRET |
| Primary sponsor | Roche Nederland B.V. |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Australia;Belarus;Belgium;Canada;China;Denmark;Finland;France;Germany;Hong Kong;Ireland;Israel;Italy;Korea (the Republic of);Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Taiwan… |
| Conditions | Metastatic Non-Small Cell Lung Cancer Metastatic Non-Small Cell Lung Cancer;Metastatic Non-Small Cell Lung Cancer |
| Interventions | It is anticipated that patients will receive at least 1 cycle of study treatment (pralsetinib if randomized to Arm A and a platinum-containing chemotherapy regimen from an Investigator's choice list of standard of care regimens if… |
| Registration date | Nov 15, 2021 |
| Target size | 10 |
| Secondary IDs | 2019-002463-10;NCT04222972;NL78806.042.21 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: